<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336142">
  <stage>Registered</stage>
  <submitdate>25/10/2010</submitdate>
  <approvaldate>1/11/2010</approvaldate>
  <actrnumber>ACTRN12610000927022</actrnumber>
  <trial_identification>
    <studytitle>A randomised Phase III Trial to assess response adapted therapy using 2-[F-18]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma</studytitle>
    <scientifictitle>A randomised Phase III Trial to assess response adapted therapy using 2-[F-18]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma</scientifictitle>
    <utrn />
    <trialacronym>RATHL HD8</trialacronym>
    <secondaryid>clinicaltrials. gov. NCT00678327</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hodgkin Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects follow different treatment courses depending on outcomes of Positron Emission Tomography (PET) scans at various stage during the trial. 


The drugs used in treatment are as follows:
bleomycin sulfate
filgrastim
pegfilgrastim
cyclophosphamide
dacarbazine
doxorubicin hydrochloride
etoposide
prednisolone
procarbazine hydrochloride
vinblastine
vincristine sulfate

Subjects undergo 2 cycles of ABVD and then have a PET scan. PET negative patients are subsequently randomised between ABVD for 4 cycles of AVD (25mg/m2 doxorubicin intravenously (i.v) days 1,15; 6mg/m2 vinblastine i.v days 1,15; Dacarbazine 375mg/m2 i.v days 1,15) for 4 cycles, before progressing to response assessment. PET positive patients undergo either 4-6 14 day cycles of BEACOPP-14 (25mg/m2 doxorubicin iv day 1; cyclophosphamide 650mg/m2 iv day 1; Etoposide 100mg/m2 i.v days 1-3; Procarbazine 100mg/m2 per oral (po) days 1-7; Prednisolone 80mg/m2 po days 1-7; Bleomycin 10,000units/m2 i.v day 8; vincristine 1.4-2mg i.v day 8; G-CSF 263/300mcg subcutaneously (s.c) days 9-13 or Peg filgastrim single dose) or 3-4 cycles of 21 day BEACOPP escalated (35mg/m2 doxorubicin i.v day 1; cyclophosphamide 1250mg/m2 i.v day 1; Etoposide 200mg/m2 i.v days 1-3; Procarbazine 100mg/m2 po days 1-7; Prednisolone 40mg/m2 po days 1-14; Bleomycin 10,000units/m2 i.v day 8; vincristine 1.4-2mg i.v day 8; G-CSF 263/300mcg s.c days 9-13 or Peg filgastrim single dose)(choice of therapy determined in advance by centre) before progressing to another PET scan. PET negative patients on this scan undergo either 2 cycles of BEACOPP-14 or 1 more cycle of BEACOPP-escalated. PET positive patients have either radiation or salvage therapy at Investigator discretion before progressing to response assessment.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival</outcome>
      <timepoint>5 years following initial PET scan following 2 cycles of ABVD (Doxorubicin 25mg/m2 iv days 1,15; Bleomycin 10,000units/m2 iv days 1,15; Vinblastine 6mg/m2 iv days 1,15; Dacarbazine 375mg/m2 iv days 1,15)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>toxicity (acute and chronic) using National Cancer Institute criteria</outcome>
      <timepoint>5 years following initial PET scan following 2 cycles of ABVD</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically confirmed classical Hodgkin lymphoma (HL) according to the current World Health Organisation Classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted). All histology will be reviewed by a central pathology panel for the group concerned
2. Aged 18 or above
3. Clinical stage IIB, IIIA, IIIB or IV, or Clinical stage IIA with adverse features:
-bulk mediastinal disease, defined as maximal transverse diameter of mass &gt;0.33 of the internal thoracic diameter at D5/6 interspace on routine chest X-ray
-outside the mediastinum, lymph node or lymph node mass greater than 10cm in diameter
-more than two sites of disease
-other poor risk features as a result of which it is considered necessary to treat with full course combination chemotherapy
4. No previous chemotherapy, radiotherapy or other investigational drug for HL
5. Performance status 0-3 
6. Adequate bone marrow function with platelets &gt; 100x10e9/l; neutrophils &gt; 1.5x10e9/l at the time of study entry unless lower numbers are attributed to bone marrow infiltration by lymphoma
7. Serum creatinine less than 150% of the upper limit of normal, serum bilirubin less than twice the upper limit of normal and transaminases &lt; 2.5Ã— upper limit of normal unless attributed to lymphoma
8. Patients with a significant history of ischaemic heart disease or hypertension must have an acceptable left ventricular ejection fraction (LVEF) =50%
9. Life expectancy &gt; 3 months
10. All patients of childbearing potential are willing to use adequate contraceptive precautions
11. Written, informed consent
12. Access to PET-CT scanning</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Poorly controlled Diabetes mellitus
2. Other concurrent uncontrolled medical condition
3. Pregnant or lactating
4. Known central nervous system or meningeal involvement by the lymphoma
5. Cardiac contra-indication to doxorubicin: abnormal contractility on echocardiography or nuclear medicine examination (MUGA)
6. Neurological contra-indication to chemotherapy (e.g. pre-existing neuropathy)
7. General status that does not allow the administration of a full course of chemotherapy according to the investigator
8. Previous history of active malignant disease other than fully excised basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix in the last 10 years
9. Known positive serology for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C (but no requirement for routine testing in the absence of risk factors)
10. Medical or psychiatric conditions that compromise the patients ability to give informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Central enrolment through the United Kingdom and allocation of trial Identification number. Follwoing enrolment all data will be collected under trial identification number.

Study is not blinded therefore no concealment of allocated treatment required.</concealment>
    <sequence>sequential number allocation in order patients are registered.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>9/09/2010</anticipatedstartdate>
    <actualstartdate>9/09/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/12/2012</actualenddate>
    <samplesize>1200</samplesize>
    <actualsamplesize>1203</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,ACT,QLD,SA,WA,NT,TAS</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Concord Repatriation Hospital - Concord</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>Royal Darwin Hospital - Tiwi</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Western Hospital - Footscray - Footscray</hospital>
    <hospital>Cairns Base Hospital - Cairns</hospital>
    <postcode>3000 - Melbourne</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>0810 - Tiwi</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>4870 - Cairns</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University College</primarysponsorname>
    <primarysponsoraddress>Gower St
London WC1E 6BT</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australasian Leukaemia and Lymphoma Group</sponsorname>
      <sponsoraddress>Level 2/10 St Andrews Place
East Melbourne, VIC,3002</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study looks at the effectiveness of using fluoro-deoxy-glucose positron emission tomography (FDG-PET) imaging to guide therapy in people with newly diagnosed, advanced Hodgkin lymphoma. 

Who is it for?

You may be able to join this study if you have previously untreated advanced Hodgkin lymphoma and are over 18 years of age. 

Trial details
Participants receive 2 cycles of the standard chemotherapy regimen (ABVD) and then have a FDG-PET scan, which provides a 3 dimensional image of the lymphoma. Depending on the results of this and future scans, participants are assigned different courses of chemotherapy at various stages during the trial. 

The trial aims to see how the different treatments, which are guided by the results of FDG-PET imaging, affect survival rates, and also monitors any toxic effects of treatment.</summary>
    <trialwebsite>http://www.cancer.gov/clinicaltrials/CRUK-2007-006064-30</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>St Andrews place
East Melbourne, VIC, 3002</ethicaddress>
      <ethicapprovaldate>14/07/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney South West Area HREC</ethicname>
      <ethicaddress>Concord Repatriation General Hospital
Concord 2139</ethicaddress>
      <ethicapprovaldate>16/12/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>16/12/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Metro South Hospital and Health Service HREC</ethicname>
      <ethicaddress>Princess Alexandra Hospital
Woollongabba
QLD 4102</ethicaddress>
      <ethicapprovaldate>8/12/2009</ethicapprovaldate>
      <hrec>09/QPAH/302</hrec>
      <ethicsubmitdate>20/05/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Northern Territories Department of Health HREC</ethicname>
      <ethicaddress>Royal Darwin Hospital Campus
Casaurina
NT 0810</ethicaddress>
      <ethicapprovaldate>15/07/2011</ethicapprovaldate>
      <hrec>2011/1609</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital HREC</ethicname>
      <ethicaddress>Hospital Ave
Nedlands 
WA 6009</ethicaddress>
      <ethicapprovaldate>10/02/2011</ethicapprovaldate>
      <hrec>2010/153</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Tasmania HREC</ethicname>
      <ethicaddress>Office of Research Services
Private Bag 1
Hoabrt
Tasmania 7001</ethicaddress>
      <ethicapprovaldate>3/11/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Judith Trotman</name>
      <address>Concord Repatriation General Hospital
Hospital Road
Concord, NSW, 2139</address>
      <phone>+61 2 9767 7243</phone>
      <fax />
      <email>Judith.Trotman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Delaine Smith</name>
      <address>ALLG
35 Elizabeth Street
Richmond
VIC 3121</address>
      <phone>+61 3 8373 9701 </phone>
      <fax />
      <email>Delaine.smith@allg.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Delaine Smith</name>
      <address>ALLG
35 Elizabth Street
Richmond 
VIC 3121</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Judith Trotman</name>
      <address>Concord Repatriation General Hospital Hospital Road Concord, NSW, 2139</address>
      <phone>+61 2 9767 7243 </phone>
      <fax />
      <email>Judith.Trotman@sswahs.nsw.gov.au </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>